The CBR1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population generated by targeted disruption of the carbonyl reductase 1 (CBR1) gene in the human Jurkat T-lymphocyte host background. This product is supplied as a heterogeneous pool of edited cells, each carrying independent gene-disrupting modifications introduced by non-homologous end joining following Cas9-mediated double-strand breaks within the CBR1 locus. The polyclonal format preserves genetic diversity within the population while achieving broad loss-of-function effects, making it suitable for pooled phenotypic analyses and large-scale screening applications without clonal selection artifacts. By eliminating functional CBR1 protein expression, this model enables systematic investigation of carbonyl reductase-dependent metabolic pathways in a T-cell leukemia context. The knockout population is validated for reduced target protein levels and is intended for use in drug metabolism, detoxification, and cancer resistance studies.
Jurkat cells are an immortalized human T-lymphocyte line originally derived from the peripheral blood of a 14-year-old male with acute T-cell leukemia. This well-characterized cell line has been indispensable for studying T-cell receptor signaling, apoptosis, HIV infection, and various aspects of lymphocyte biology. Jurkat cells exhibit constitutive activation of proximal TCR signaling components and are responsive to stimuli that trigger IL-2 production, NFAT activation, and apoptotic cascades, providing a robust platform for dissecting signal transduction mechanisms. Their origin from a leukemia patient makes them particularly relevant for modeling leukemic T-cell behavior and evaluating antineoplastic drug responses. The integration of a CBR1 knockout into this host enables exploration of how carbonyl reductase activity modulates drug sensitivity and cellular redox homeostasis within a malignant T-cell milieu.
CBR1 encodes an NADPH-dependent carbonyl reductase that catalyzes the reduction of a broad spectrum of endogenous and exogenous carbonyl substrates. Central to its catalytic function, CBR1 requires the cofactor NADPH to transfer hydride ions to carbonyl groups, converting substrates such as the anthracycline chemotherapeutic doxorubicin to its less cytotoxic metabolite doxorubicinol. This detoxification reaction is a key determinant of anthracycline resistance in cancer cells. CBR1 also participates in prostaglandin metabolism by reducing 15-keto-PGE2 to 13,14-dihydro-15-keto-PGE2 and modifying PGF2?? derivatives, linking it to inflammatory signaling pathways. The gene is transcriptionally regulated by oxidative stress-responsive factors NRF2 and AhR, and its expression can be induced by pro-inflammatory cytokines IL-1?? and TNF-??. Functionally, CBR1 operates downstream of these regulators and directly influences the intracellular levels of reduced drug metabolites and prostaglandin derivatives, thereby impacting cellular responses to xenobiotic stress and inflammatory cues.
Within the Jurkat cell context, CBR1 disruption provides critical insights into the determinants of drug-induced cytotoxicity and resistance in T-cell acute lymphoblastic leukemia (ALL). The knockout model enables direct assessment of how loss of carbonyl reduction affects doxorubicin and daunorubicin sensitivity, as the conversion of these agents to their less potent alcohol metabolites is a well-documented resistance mechanism. Because Jurkat cells retain functional apoptotic machinery, researchers can dissect the interplay between CBR1-mediated detoxification and cell death pathways triggered by anthracyclines. This model also facilitates studies of endogenous prostaglandin regulation in T cells, as CBR1 contributes to the degradation of signaling prostanoids such as PGE2 and PGF2??, thereby potentially modulating immune effector functions. By eliminating CBR1 activity, the engineered cells become hypersensitive to carbonyl-containing substrates and dependent on alternative detoxification routes, revealing compensatory mechanisms operative in leukemic lymphocytes.
Investigators can employ this polyclonal knockout population to address a range of experimental questions in drug metabolism and cancer biology. Typical applications include quantifying doxorubicinol formation via HPLC or LC-MS to confirm abrogated metabolic conversion, performing doxorubicin dose?Cresponse viability assays by MTT or flow cytometry to establish resistance profiles, and screening small-molecule CBR1 inhibitors to chemosensitize leukemia cells. Western blotting and RT-qPCR are used to validate CBR1 protein and mRNA knockdown, respectively, while NADPH consumption assays and ROS measurements probe the cellular redox balance. The model also supports prostaglandin reduction assays and analysis of arachidonic acid metabolism, linking CBR1 function to inflammatory regulation in T lymphocytes. Additionally, oxidative stress induction experiments can delineate the role of NRF2-mediated CBR1 upregulation in adaptive antioxidant responses. For further inquiries or to discuss experimental design, please contact Ascent Research.
